Down Syndrome
Cross-source consensus on Down Syndrome from 1 sources and 5 claims.
1 sources · 5 claims
Uses
How it works
Risks & contraindications
Comparisons
Background
Highlighted claims
- Participants must have free trisomy 21 documented by karyotyping and a mental age between 4.5 and 8.5 years. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
- Down syndrome is the leading cause of genetically defined intellectual disability worldwide. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
- Cognitive impairment in Down syndrome includes low IQ, planning difficulties, memory impairment, and reduced adaptive behaviour and autonomy. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
- The estimated global incidence of Down syndrome is approximately 1 in 700–800 live births, with 40–50 million people affected worldwide. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
- Hippocampal dysfunction and frontal cortex abnormalities are strongly linked to cognitive impairments in Down syndrome. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial